IMVT: Immunovant, Inc.
About
Immunovant, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling normal lives for patients with autoimmune diseases. It is developing a novel, fully human monoclonal antibody IMVT-1401 that selectively binds to and inhibits the neonatal fragment crystallizable receptor. The company was founded in 2018 and is headquartered in New York, NY.
Current Value
$25.371 Year Return
Current Value
$25.371 Year Return
Key Details
Market Cap
$3.70B
P/E Ratio
-11.38
1Y Stock Return
-23.48%
1Y Revenue Growth
0.00%
Dividend Yield
0.00%
Price to Book
8.2
Strategies that include IMVT
Stock's related to IMVT
Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| RVMD | 41.74% | $9.50B | +171.62% | 0.00% |
| SNDX | 39.71% | $1.35B | +2.87% | 0.00% |
| ARGX | 36.28% | $34.68B | +17.58% | 0.00% |
| KYMR | 36.15% | $2.77B | +125.95% | 0.00% |
| FOLD | 35.87% | $2.84B | -11.52% | 0.00% |
| CRNX | 35.20% | $5.12B | +84.27% | 0.00% |
| APLS | 34.35% | $3.61B | -41.27% | 0.00% |
| SHO | 33.73% | $2.02B | +3.53% | 3.20% |
| IOVA | 33.61% | $2.50B | +58.41% | 0.00% |
| GIII | 32.92% | $1.28B | +4.84% | 0.00% |
| BFH | 31.90% | $2.86B | +114.97% | 1.45% |
| ABUS | 31.74% | $661.33M | +90.71% | 0.00% |
| ATXS | 31.64% | $550.23M | +114.29% | 0.00% |
| PGEN | 31.57% | $228.91M | -28.00% | 0.00% |
| AZTA | 31.23% | $2.00B | -28.24% | 0.00% |
| ORC | 31.09% | $615.55M | +6.95% | 18.46% |
| ZUMZ | 30.97% | $409.63M | +17.32% | 0.00% |
| SCVL | 30.97% | $914.94M | +41.95% | 1.57% |
| OLO | 30.91% | $1.06B | +30.00% | 0.00% |
| RCUS | 30.81% | $1.33B | +5.07% | 0.00% |
Uncorrelated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| CREG | 0.04% | $6.14M | -35.78% | 0.00% |
| AIFU | -0.04% | $67.49M | -83.02% | 0.00% |
| INSG | 0.05% | $157.28M | +540.25% | 0.00% |
| FATBB | 0.05% | $81.94M | -12.91% | 11.69% |
| IMNN | -0.12% | $10.02M | -22.89% | 0.00% |
| TKC | 0.13% | $5.80B | +35.51% | 1.30% |
| KO | -0.13% | $269.63B | +7.86% | 3.07% |
| OR | -0.15% | $3.69B | +45.97% | 0.94% |
| CYCN | -0.16% | $4.77M | -16.19% | 0.00% |
| CME | 0.19% | $82.76B | +9.21% | 1.98% |
| QUAD | -0.23% | $366.66M | +43.76% | 2.84% |
| SMC | -0.34% | $383.35M | +97.26% | 0.00% |
| KDP | -0.38% | $42.76B | -1.22% | 2.77% |
| EZPW | -0.39% | $655.76M | +45.24% | 0.00% |
| CANG | -0.40% | $253.50M | +212.50% | 0.00% |
| CI | -0.41% | $89.70B | +12.57% | 1.68% |
| FAT | -0.46% | $89.30M | -11.53% | 10.73% |
| STKL | -0.46% | $894.47M | +55.49% | 0.00% |
| WMK | -0.47% | $1.88B | +14.23% | 1.95% |
| NTIC | -0.50% | $132.27M | +24.98% | 2.02% |
Inversely Correlated Stocks
| Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
|---|---|---|---|---|
| SMMT | -18.98% | $14.74B | +910.10% | 0.00% |
| DOGZ | -13.12% | $614.77M | +1,372.26% | 0.00% |
| MCK | -11.91% | $78.15B | +35.51% | 0.42% |
| HUSA | -11.68% | $16.69M | -11.56% | 0.00% |
| BTCT | -10.08% | $42.61M | +353.33% | 0.00% |
| SYPR | -8.28% | $32.23M | -26.32% | 0.00% |
| BSM | -7.81% | $3.17B | -13.01% | 10.65% |
| BYRN | -7.77% | $479.70M | +295.19% | 0.00% |
| TCTM | -7.70% | $8.10M | -42.99% | 0.00% |
| PRT | -7.70% | $48.72M | -16.56% | 10.33% |
| FWONK | -7.31% | $20.20B | +25.99% | 0.00% |
| PULM | -7.21% | $19.83M | +202.98% | 0.00% |
| WHLM | -7.12% | $17.64M | -29.34% | 0.00% |
| UUU | -7.11% | $4.97M | -41.89% | 0.00% |
| APD | -6.85% | $72.92B | +18.69% | 2.14% |
| OCX | -6.64% | $42.93M | -36.09% | 0.00% |
| NAT | -6.44% | $636.83M | -30.05% | 13.79% |
| DMLP | -6.24% | $1.58B | +18.00% | 10.54% |
| LQDA | -5.87% | $859.91M | +53.94% | 0.00% |
| NAPA | -5.48% | $1.63B | +9.61% | 0.00% |
ETF's related to IMVT
Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| XBI | 46.32% | $6.58B | 0.35% |
| IBB | 45.47% | $6.66B | 0.45% |
| FBT | 41.88% | $1.11B | 0.56% |
| PTH | 41.78% | $143.31M | 0.6% |
| XPH | 41.27% | $157.87M | 0.35% |
| RSPA | 40.39% | $273.87M | 0% |
| GNOM | 40.06% | $70.59M | 0.5% |
| BBH | 39.82% | $397.87M | 0.35% |
| PBE | 39.43% | $258.53M | 0.58% |
| EFAA | 38.78% | $117.38M | 0% |
| FXH | 38.36% | $1.15B | 0.62% |
| ARKG | 37.32% | $1.13B | 0.75% |
| IHE | 36.25% | $596.23M | 0.39% |
| QQEW | 36.19% | $1.90B | 0.57% |
| ISCG | 36.12% | $640.00M | 0.06% |
| XT | 35.99% | $3.38B | 0.46% |
| FXL | 35.95% | $1.39B | 0.62% |
| SECT | 35.95% | $2.00B | 0.77% |
| WCLD | 35.93% | $454.67M | 0.45% |
| BUFR | 35.71% | $5.69B | 0.95% |
Uncorrelated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| CSHI | 0.08% | $482.85M | 0.38% |
| SGOV | 0.39% | $27.53B | 0.09% |
| FMF | -0.85% | $244.61M | 0.95% |
| CORN | 1.10% | $61.12M | 0.2% |
| KRBN | -1.11% | $242.47M | 0.85% |
| BOXX | -1.14% | $4.43B | 0.1949% |
| XHLF | -1.17% | $874.27M | 0.03% |
| BILZ | -1.65% | $563.02M | 0.14% |
| TPMN | 1.73% | $40.60M | 0.65% |
| SHV | 1.80% | $18.13B | 0.15% |
| CCOR | 1.80% | $109.04M | 1.18% |
| SOYB | -1.80% | $27.32M | 0.22% |
| DBMF | 2.07% | $1.02B | 0.85% |
| XBIL | 2.14% | $637.70M | 0.15% |
| DEFI | 2.29% | $13.58M | 0.94% |
| MTBA | 2.81% | $1.56B | 0.15% |
| CANE | 2.82% | $17.72M | 0.29% |
| BITO | 2.83% | $2.65B | 0.95% |
| GBIL | 2.92% | $5.60B | 0.12% |
| BTF | 3.25% | $51.69M | 1.24% |
Inversely Correlated ETFs
| Name | Correlation | AUM | Expense Ratio |
|---|---|---|---|
| VIXY | -28.04% | $195.31M | 0.85% |
| BTAL | -26.50% | $388.04M | 1.43% |
| TAIL | -22.34% | $67.98M | 0.59% |
| TBIL | -10.07% | $4.38B | 0.15% |
| USDU | -9.89% | $201.97M | 0.5% |
| CTA | -9.87% | $350.27M | 0.78% |
| ULST | -9.15% | $535.47M | 0.2% |
| AGZD | -8.73% | $142.76M | 0.23% |
| EDV | -8.63% | $3.88B | 0.06% |
| GOVZ | -8.58% | $313.00M | 0.1% |
| UUP | -8.56% | $309.25M | 0.77% |
| ZROZ | -8.48% | $1.63B | 0.15% |
| MINT | -8.40% | $11.62B | 0.35% |
| SCHQ | -8.33% | $762.08M | 0.03% |
| VGLT | -8.19% | $12.70B | 0.04% |
| SPTL | -8.08% | $10.33B | 0.03% |
| TLH | -8.07% | $7.01B | 0.15% |
| TLT | -8.03% | $57.46B | 0.15% |
| DBA | -8.00% | $755.88M | 0.93% |
| HDRO | -7.35% | $164.26M | 0.3% |
News
Yahoo
Q2 2024 Roivant Sciences Ltd Earnings Call
Yahoo
IMVT reports dismal second-quarter fiscal 2025 results. It is on track to initiate several studies on IMVT-1402 across various autoimmune indications.
Yahoo
Five Investigational New Drug (IND) applications cleared across a range of therapeutic areas and FDA divisions for lead asset, IMVT-1402Proof of concept data from batoclimab trial in Graves’ disease (GD) demonstrate potential of deeper IgG reduction with potent FcRn inhibition to transform treatment for GD patients who are not well controlled on antithyroid drugs (ATDs); initiation of potentially registrational trial to evaluate IMVT-1402 in GD expected by year endIND cleared for IMVT-1402 in rh
Finnhub
Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 •Five Investigational New Drug applications cleared...
Finnhub
NEW YORK - Immunovant, Inc. , a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of...
Yahoo
NEW YORK, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today announced that data from the Phase 2a trial of batoclimab in Graves’ disease will be the subject of an oral presentation of a late-breaking abstract accepted for the 2024 American Thyroid Association (ATA) Annual Meeting being held October 30 to November 3, 2024, in Chicago, Illinois. New data highlighting b
Disclaimer
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.